James Thompson, PhDCMC Therapeutic Area Lead at Moderna Therapeutics
Dr. Thompson has assumed several roles in since joining Moderna in November 2013, including Head of CMC and Analytical Development and Interim Head of Regulatory Affairs. Dr. Thompson is currently CMC Therapeutic Area Lead for Moderna’s rare disease, oncology and cardiovascular programs. Dr. Thompson is also Chair of Moderna’s Specification Committee. Dr. Thompson has been in the RNA therapeutics field for over 28 years since joining Ribozyme Pharmaceuticals in 1991. Prior to joining Moderna, Dr. Thompson was Vice President Development at Quark Pharmaceuticals, Inc. developing siRNA therapeutics, and before this was Director of Research & Development at Genta, Inc. developing RNA-based therapeutics and delivery systems. Dr. Thompson received a BS in Biology from Temple University and a Ph.D. in Biological Chemistry from Hahnemann University in Philadelphia.